Stay informed with our newsletter.
.webp){kind=spacer}
EN
.webp)
Boston Brand Media news Boehringer Ingelheim's drug survodutide demonstrates potential in treating liver fibrosis. Early results indicate efficacy in combating the progressive scarring of the liver, offering hope for patients with this condition. The development marks a significant advancement in addressing liver diseases, potentially improving outcomes for affected individuals.
Boehringer Ingelheim has unveiled promising results from a Phase II trial of survodutide, showing a notable improvement in liver fibrosis among patients.
According to a sub-analysis presented at the European Association for the Study of the Liver Congress (EASL) 2024 and published in The New England Journal of Medicine, up to 64.5% of adults with moderate to advanced scarring (fibrosis stages F2 and F3) experienced improvement without worsening metaboli dysfunction-associated steatohepatitis (MASH) after 48 weeks of treatment with survodutide, compared to 25.9% with placebo.
Boston Brand Media also found the study revealed that up to 52.3% of adults treated with survodutide achieved a significant improvement in liver scarring across stages F1 to F3, versus 25.8% with placebo.
Dr. Arun Sanyal, Professor of Medicine at Virginia Commonwealth University School of Medicine and Principal Investigator of the trial, expressed excitement about the findings, stating that the potential of glucagon agonism, along with GLP-1, to improve MASH and fibrosis is significant.
Survodutide, a glucagon/GLP-1 receptor dual agonist, stands out as the first drug to demonstrate such a level of fibrosis benefit in a phase 2 MASH trial.
The drug's mechanism, including increasing energy expenditure and impacting the liver directly, could contribute to fibrosis improvement, while its GLP-1 agonist component decreases appetite and increases satiety.
These results position survodutide as a potential game-changer for individuals living with MASH and clinically significant fibrosis, offering hope for a condition that affects over 115 million people worldwide and can lead to severe complications, such as liver cancer and the need for liver transplantation. Additionally, the trial demonstrated significance versus placebo for all other secondary endpoints after 48 weeks of treatment.
For questions or comments write to writers@bostonbrandmedia.com
Source: Pharmatimes
